1:59 PM
 | 
Jan 02, 2018
 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatic screens; cell-free assays

A low-cost computational method for quantifying tumor cfDNA could identify cancer patients eligible for high-cost, whole-exome sequencing-based personalized medicine. The method quantifies tumor cfDNA in blood using the low-cost method of ultra low-pass, whole-genome sequencing and probabilistic inference of copy number alterations, a hallmark of tumor cfDNA, then uses the inferred...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$18 USD
More Info >